57th ASH Annual Meeting and Exposition (December 5-8, 2015): 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I

CLL: Biology and Pathophysiology, excluding Therapy Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

CD49d Prevails over the Novel Recurrent Mutations As Independent Prognosticator of Overall Survival in Chronic Lymphocytic Leukemia

Michele Dal Bo¹^*, Pietro Bulian²^*, Riccardo Bomben¹^*, Antonella Zucchetto¹^*, Francesca Rossi¹^*, Federico Pozzo¹^*, Tamara Bittolo¹^*, Paola Nanni¹^*, Ilaria Cattarossi¹^*, Eva Zaina¹^*, Hillarj Chivilò¹^*, Massimo Degan¹^*, Francesco Zaja, MD³, Gabriele Pozzato⁴, Annalisa Chiarenza⁵^*, Francesco Di Raimondo, MD/PhD⁶, Giovanni Del Poeta, Pr, MD⁷, Davide Rossi, MD, PhD⁸, Gianluca Gaidano⁹ and Valter Gattei¹

¹Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy
²Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy
³Centro Trapianti e Terapie Cellulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy
⁴Department of Internal Medicine and Haematology, Maggiore General Hospital, University of Trieste, Trieste, Italy
⁵Division of Hematology, Ferrarotto Hospital, Catania, Italy
⁶Section of Hematology, A.O.U. Policlinico "Vittorio Emanuele", Catania, Italy
⁷Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Roma, Italy
⁸Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
⁹Division of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

1707

In Depth Characterization of CLL with Normal Karyotype By Array CGH and Mutation Screening

Claudia Haferlach, MD, Sabine Jeromin, PhD^*, Wolfgang Kern, MD, Susanne Schnittger, PhD and Torsten Haferlach

MLL Munich Leukemia Laboratory, Munich, Germany

1708

Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication

Erika Tissino¹^*, Chiara Caldana¹^*, Dania Benedetti¹^*, Francesca Rossi¹^*, Michele Dal Bo¹^*, Pietro Bulian²^*, Riccardo Bomben¹^*, Francesco Zaja, MD³, Annalisa Chiarenza⁴^*, Tanja Nicole Hartmann⁵^*, Alexandre Chigaev⁶^*, Giovanni Del Poeta⁷, Valter Gattei¹ and Antonella Zucchetto¹^*

¹Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy
²Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy
³Centro Trapianti e Terapie Cellulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy
⁴Division of Hematology, Ferrarotto Hospital, Catania, Italy
⁵Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
⁶Department of Pathology and Cancer Center, University of New Mexico, Albuquerque, NM
⁷Division Hematology, S.Eugenio Hospital and University of Tor Vergata, Rome, Italy

1709

The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide

Hila Shaim, MD¹^*, Zeev Estrov, MD², Takuya Sekine¹^*, Kayo Kondo, PhD¹^*, Peter P. Ruvolo, PhD², Philip Thompson, MBBS²^*, Anushruti Sarvaria, MS¹^*, Muharrem Muftuoglu¹^*, Nobuhiko Imahashi, MD, PhD¹^*, Enli Liu, MD, MS¹^*, Catherine Sobieski¹^*, William Wierda, MD, PhD³, Michael J. Keating, MD², Nina Shah, MD¹, Chitra M. Hosing, MD¹, Abdullah Alsuliman¹^*, Rafet Basar, MD¹^*, Alessandra Ferrajoli, MD², Elizabeth J. Shpall, MD¹ and Katayoun Rezvani, MD PhD¹

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

1710

Overexpression of Activation-Induced Deaminase in TCL1 Mice Leads to the Development of IGHV-Mutated and -Unmutated CLL Clones That Resemble Unique Subsets of Human CLL

Xiao-Jie Yan, MD, PhD¹, Pablo Morande, PhD²^*, Ezra B Kolitz, BS¹^*, Crystal D Grant, BS¹^*, Gautam Nayyar¹^*, Pablo Oppezzo, Ph.D.²^* and Nicholas Chiorazzi, MD.¹

¹The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY
²Institut Pasteur de Montevideo, Montevideo, Uruguay

1711

Genetic Inhibition of PI3K p110delta Antagonizes Survival Signals and Induces Immune Activation in Chronic Lymphocytic Leukemia (CLL)

Shuai Dong, MS¹, John C. Byrd, MD^2,3 and Amy J. Johnson, PhD^2,3

¹Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH
²Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
³Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

1712

ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome

Veronika Navrkalova, PhD^1,2,3^*, Emma Young³^*, Panagiotis Baliakas³^*, Lenka Radova¹^*, Karla Plevova, Ph.D.^1,4^*, Lesley-Ann Sutton³^*, Larry Mansouri³^*, Viktor Ljungstrom³^*, Stavroula Ntoufa⁵^*, Zadie Davis⁶^*, Gunnar Juliusson, M.D, Ph.D.⁷, Karin E Smedby, MD, PhD⁸^*, Chrysoula Belessi⁹, Panagiotis Panagiotidis¹⁰^*, Frederic Davi, MD, PhD¹¹^*, Anton W. Langerak¹²^*, Paolo Ghia, MD, PhD¹³, Jonathan C Strefford, PhD¹⁴, David G Oscier⁶, Kostas Stamatopoulos⁵^*, Sarka Pospisilova^1,2^*, Richard Rosenquist³ and Martin Trbusek, Ph.D.^1,4^*

¹Central European Institute of Technology, Masaryk University, Brno, Czech Republic
²Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
⁴Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
⁵Institute of Applied Biosciences, CERTH, Thessaloniki, Greece
⁶Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
⁷Department of Laboratory Medicine, Stem Cell Center, Hematology and Transplantation, Lund University, Lund, Sweden
⁸Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
⁹Hematology Department, Nikea General Hospital, Piraeus, Greece
¹⁰First Department of Propaedeutic Medicine, University of Athens, Athens, Greece
¹¹Department of Biological Hematology, Pitie-Salpetriere Hospital and Pierre et Marie Curie University, Paris, France
¹²Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
¹³Division of Experimental Oncology and Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy
¹⁴Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom

1713

High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia

Bing Cui, PhD¹^*, Liguang Chen, MD, PhD¹^*, Laura Z. Rassenti, PhD², Emanuela M. Ghia, PhD³, Jian Yu, PhD¹^*, Ling Zhang, PhD¹^*, Donna S Neuberg, ScD⁴, William Wierda, MD, PhD⁵, Michael Keating, MBBS⁶, Kanti R. Rai, MD⁷, Neil E. Kay, MD⁸, Jennifer R. Brown, MD, PhD⁹, John C. Byrd, MD¹⁰, John Gribben, MD, DSc^11,12 and Thomas J. Kipps, M.D., PhD.¹

¹Moores Cancer Center, University of California, San Diego, La Jolla, CA
²University of California San Diego, Moores Cancer Center, La Jolla, CA
³Moores UCSD Cancer Center, CLL Research Consortium, San Diego, CA
⁴Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
⁵University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY
⁸Division of Hematology, Mayo Clinic, Rochester, MN
⁹Medical Oncology, Dana Farber Cancer Institute, Boston, MA
¹⁰Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
¹¹Barts Cancer Center, The London School of Medicine, London, United Kingdom
¹²Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

1714

Sphingosine Kinases (SK): Key Molecules Associated with the Activation, Proliferation and Ibrutinib-Induced Cell Death of Chronic Lympocytic Leukemia Cells

Maria Belen Almejun, Ph.D.¹^*, Mercedes Borge, Ph.D.^1,2^*, Ana Colado¹^*, Enrique Podaza¹^*, Denise Risnik¹^*, Carlos Daniel De Brasi³^*, Pablo Oppezzo, Ph.D.⁴^*, Maria Cabrejo, MD⁵^*, Horacio Fernandez Grecco, MD,⁵^*, Raimundo F. Bezares, MD⁶^*, Santiago C Cranco, MD⁷^*, Ruben A. Burgos, MD,⁷^*, Julio Cesar Sanchez Avalos, MD⁷, Mirta N. Giordano, PhD^1,2^* and Romina Gamberale, Ph.D.^1,2^*

¹Laboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina
²Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
³Laboratorio de Genética Molecular de la Hemofilia, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina
⁴Institut Pasteur de Montevideo, Montevideo, Uruguay
⁵Sanatorio Municipal Dr. Julio Mendez, Buenos Aires, Argentina
⁶Hospital General de Agudos Dr. Teodoro Alvarez, Buenos Aires, Argentina
⁷Instituto Alexander Fleming, Buenos Aires, Argentina

1715

The T-Cell/CLL/Macrophage Triad Shapes a Supportive Tumor Microenvironment in CLL

Martijn H.A. van Attekum, MD^1,2^*, Sanne Terpstra^1,2^*, Emilie Reinen³^*, Marieke Von Lindern, PhD⁴^*, Erik Slinger, PhD⁵^*, Eldering Eric, PhD^1,6^* and Arnon P. Kater, MD, PhD^7,8

¹Experimental Immunology, Academic Medical Center Amsterdam, Amsterdam, Netherlands
²Hematology, Academic Medical Center Amsterdam, Amsterdam, Netherlands
³Academic Medical Center Amsterdam, Amsterdam, Netherlands
⁴Sanquin Blood Supply, Amsterdam, Netherlands
⁵Departments of Experimental Immunology and Hematology, Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam, Netherlands
⁶Lymphoma and Myeloma Center, LYMMCARE, Amsterdam, Netherlands
⁷Department of Hematology, Academic Medical Center, Amsterdam, Netherlands
⁸Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, Netherlands

1716

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Matthew D Blunt, PhD¹^*, Jack Parnell, BSc(hons)¹^*, Marta Larrayoz, PhD¹^*, Lindsay Smith, PhD¹^*, Rachel Dobson, BSc(Hons)¹^*, Jonathan C Strefford, PhD¹, Freda K Stevenson, DPhil¹, Francesco Forconi, MD, DM, PhD, FRCPath²^*, Andrew J Davies, MRCP³^*, Peter W Johnson, MD⁴, Graham Packham, PhD¹^*, Greg P. Coffey, PhD⁵^*, Mark S Cragg, PhD⁶^* and Andrew J Steele, PhD¹

¹Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom
²Cancer Sciences Unit, Haematological Oncology Group, University of Southampton, Southampton, United Kingdom
³Southampton University, SCTU, Southampton, United Kingdom
⁴Cancer Research UK Clinical Centre, University of Southampton, Southampton, United Kingdom
⁵Portola Pharmaceuticals Inc, South San Francisco, CA
⁶Cancer Sciences Unit, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom

1717

The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring

Andy C Rawstron¹, Dena Cohen²^*, Ruth Mary De Tute¹^*, Lucy McParland²^*, Laura Collett²^*, David Phillips²^*, Anna Chalmers²^*, Abraham Mullasseril Varghese¹^*, Talha Munir, MBBS, MRCP, FRCPath¹^*, Walter M Gregory²^* and Peter Hillmen¹

¹St. James's Institute of Oncology, Leeds, United Kingdom
²Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

1718

Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL)

Giovanni Del Poeta¹, Michele Dal Bo²^*, Francesco Buccisano¹, Federico Pozzo²^*, Maria Ilaria Del Principe, MD¹^*, Pietro Bulian³^*, Davide Rossi, MD, PhD⁴, Adriano Venditti, MD¹, Paolo de Fabritiis¹^*, Gianluca Gaidano, MD, PhD⁴, Sergio Amadori, MD¹ and Valter Gattei²

¹Hematology, University Tor Vergata, Rome, Italy
²Clinical and Experimental Onco-Hematology Unit, CRO, IRCCS, Aviano (PN), Italy
³Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy
⁴Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

1719

SLP76 Is Ectopically Expressed in Chronic Lymphocytic Leukemia Cells and Involves in B-Cell Receptor Signaling

Yair Herishanu, MD^1,2, Nili Dorozella³^*, Mika Shapiro, Ph.D.³^*, Chava Perry, MD/Ph.D.¹^* and Ben-Zion Katz, Ph.D.^3,4^*

¹Department of Hematology and Bone Marrow Transplantation, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
²Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
³Tel-Aviv Sourasky Medical Center, Department of Hematology, Tel-Aviv, Israel
⁴Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

1720

The Concomitant High Expression of the B-Cell Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Context of Low-Risk Chronic Lymphocytic Leukemia

Antonella Zucchetto¹^*, Dania Benedetti¹^*, Chiara Caldana¹^*, Erika Tissino¹^*, Michele Dal Bo¹^*, Pietro Bulian²^*, Riccardo Bomben¹^*, Francesca Rossi¹^*, Francesco Zaja, MD³, Gabriele Pozzato⁴, Annalisa Chiarenza⁵^*, Francesco Di Raimondo, MD/PhD⁶, Giovanni Del Poeta⁷ and Valter Gattei¹

¹Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy
²Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy
³Centro Trapianti e Terapie Cellulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy
⁴Department of Internal Medicine and Haematology, Maggiore General Hospital, University of Trieste, Trieste, Italy
⁵Division of Hematology, Ferrarotto Hospital, Catania, Italy
⁶Section of Hematology, A.O.U. Policlinico "Vittorio Emanuele", Catania, Italy
⁷Division Hematology, S.Eugenio Hospital and University of Tor Vergata, Rome, Italy

1721

Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53

Sabine Jeromin, PhD^*, Wolfgang Kern, MD, Richard Schabath^*, Tamara Alpermann^*, Niroshan Nadarajah, M.Sc.^*, Manja Meggendorfer, PhD^*, Susanne Schnittger, PhD, Torsten Haferlach and Claudia Haferlach, MD

MLL Munich Leukemia Laboratory, Munich, Germany

1722

Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers

Juliane S Stickel, MD¹^*, Daniel Johannes Kowalewski²^*, Heiko Schuster²^*, Stefan Kahn¹^*, Linus Backert³^*, Lothar Kanz, MD¹, Helmut R Salih, MD^1,4, Hans-Georg Rammensee, PhD²^* and Stefan Stevanovic, PhD²^*

¹Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany
²Department of Immunology, Interfaculty Institute of Cell Biology, University of Tübingen, Tuebingen, Germany
³Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tuebingen, Tuebingen, Germany
⁴Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site Tuebingen, Tuebingen, Germany

1723

EBV-Specific CD8⁺ T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia

Tom Hofland^1,2^*, Iris de Weerdt^1,2^*, Sanne Terpstra^1,2^*, Ester B.M. Remmerswaal, PhD^2,3^*, Ineke J.M. ten Berge, MD, PhD^2,3^*, Arnon P. Kater, MD, PhD^1,4 and Sanne H. Tonino, MD, PhD^1,4^*

¹Department of Hematology, Academic Medical Center, Amsterdam, Netherlands
²Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands
³Renal Transplant Unit, Academic Medical Center, Amsterdam, Netherlands
⁴Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, Netherlands

1724

Eµ-TCL1mTerc^-/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

Annika Scheffold, M.Sc.¹^*, Billy Michael Chelliah Jebaraj, PhD¹^*, André Lechel, PhD²^*, Sarah-Fee Katz, PhD²^*, Daniela Steinbrecher, M.Sc.¹^*, Vanni Torresi, M.Sc.¹^*, Christof Schneider, MD¹^*, Daniel Mertens, PhD¹^*, Hartmut Döhner, MD³, Karl-Lenhard Rudolph, MD⁴^* and Stephan Stilgenbauer, MD¹

¹Department of Internal Medicine III, University of Ulm, Ulm, Germany
²Department of Internal Medicine I, University of Ulm, Ulm, Germany
³Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
⁴Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany

1725

Intratumoral Genetic Heterogeneity Provides Additional Prognostic Significance of the CLL Genomic Features

Wenjie Xiong¹^*, Heng Li¹^*, Shuhua Yi, MD, PhD²^*, Zengjun Li Sr.¹^*, Shizhen Zhong¹^*, Wei Liu¹^*, Dehui Zou³^* and Lugui Qiu, MD, PhD⁴

¹State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
²State Key Lab of Experimental Hematology,Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
³Institute of Hematology and Blood Disease Hospital,, Chinese Academy of Medical Sciences and Peking Union Medical College, tianjin, China
⁴State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China

1726

Ethnic Difference in Genomic Profiles of Chronic Lymphocytic Leukemia in Korea: Targeted Exome Sequencing and Molecular Cytogenetics

Jung-Ah Kim, MD¹^*, Byungjin Hwang²^*, Si Nae Park³^*, Sunghoon Huh²^*, Kyongok Im, B.S³^*, Seon Young Kim, MD, PhD¹^*, Joo Ryung Huh, MD, PhD⁴^*, Eul-Ju Seo, MD, PhD⁵^*, Je-Hwan Lee, MD, PhD⁶, Sunghoon Kwon, PhD⁷^*, Sung-Soo Yoon, MD PhD⁸, Duhee Bang, PhD²^* and Dong Soon Lee¹

¹Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea
²Yonsei University, Seoul, South Korea
³Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
⁴Asan Medical Center, Seoul, South Korea
⁵Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea
⁶Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
⁷Seoul National University, Seoul, South Korea
⁸Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

1727

Fcgammariib Expression As a Prognostic Marker in Chronic Lymphocytic Leukemia

Rosa Bosch^1,2^*, Gerardo Ferrer^3,4^*, Eva Puy Vicente²^*, Alba Mora^1,2^*, Rajendra N. Damle³^*, Sergey Gorlatov⁵^*, Kanti Rai⁶^*, Emili Montserrat⁷, Jorge Sierra², Nicholas Chiorazzi³^* and Carol Moreno²^*

¹Laboratory of Oncological Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain
²Department of Hematology, Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona, Barcelona, Spain
³Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY
⁴Laboratory of Translational Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, Barcelona, Spain
⁵MacroGenics, Inc., Rockville, MD
⁶Hematology/Oncology, Oncology LIJ Medical Center, Lake Success, NY
⁷Department of Hematology, Hospital Clinic, Barcelona, Spain

1728

SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy

Cinzia Bologna^1,2^*, Roberta Buonincontri, PhD^1,2^*, Sara Serra, PhD²^*, Tiziana Vaisitti, PhD^1,2, Valentina Audrito, PhD²^*, Davide Brusa, PhD^1,2^*, Andrea Pagnani²^*, Marta Coscia³^*, Giovanni D'Arena⁴^*, Erica B. Bhavsar⁵^*, Richard R. Furman⁶^*, Davide Rossi, MD, PhD⁷, Gianluca Gaidano⁸, Cox Terhorst⁹^* and Silvia Deaglio^1,2

¹Department of Medical Sciences, University of Turin, Turin, Italy
²Human Genetics Foundation, Turin, Italy
³Division of Hematology, AO Città della Salute e della Scienza, Turin, Italy
⁴Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
⁵Department of Hematology/Oncology, Weill Cornell Medical College, New York, NY
⁶Weill Medical College of Cornell University, New York, NY
⁷Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
⁸Division of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
⁹Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

1729

Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis

Sabrina Bossio¹^*, Laura De Stefano¹^*, Mariavaleria Pellicanò, PhD¹^*, Angela Palummo¹^*, Francesca Storino¹^*, Nadia Caruso²^*, Giovanni Iaquinta¹^*, Giovanna Cutrona, PhD³^*, Massimo Gentile, MD⁴^*, Ernesto Vigna⁵^*, Anna Grazia Recchia, PhD¹^*, Fortunato Morabito, MD^6,7^* and Antonino Neri, MD⁸

¹Unità di Ricerca Biotecnologica, Aprigliano (CS), Italy
²Department of Onco-hematology, A.O. of Cosenza, Cosenza, Italy, Cosenza, Italy
³UO Molecular Patology, IRCCS San Martino-IST, Genoa, Italy
⁴U.O.C. di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy
⁵Hematology Unit, A.O. of Cosenza, Cosenza, Italy, Cosenza, Italy
⁶Section of Hematology, A.O. L'Annunziata of Cosenza, Cosenza, Italy
⁷Biotechnology Research Unit, Aprigliano (Cosenza), Italy
⁸Centro di Ricerca per lo Studio delle Leucemie, Fondazione IRCCS, Università di Milano, Milano, Italy

1730

RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

Rashmi Kanagal-Shamanna, MD¹^*, Raja Luthra, PhD¹^*, Madan Luthra, PhD¹^*, Xinyan Lu, M.D.¹^*, Mark Routbort, MD, PhD¹^*, Nitin Jain, MD², Michael Keating, MBBS², L Jeffrey Medeiros, MD¹, William Wierda, MD, PhD³ and Keyur P. Patel, MD, PhD¹^*

¹Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

1731

Role of Prostate Apoptosis Response-4 Tumor Suppressor in the Survival and Growth of Chronic Lymphocytic Leukemia

Sunil K Nooti, Ph.D.^1,2^*, Mary K McKenna, B.S.¹^*, Frank W Frissora, M.S.³^*, Beth W Gachuki, M.S.¹^*, Sara S Alhakeem, M.S.¹^*, Joseph T Greene, M.S.³^*, Natarajan Muthusamy, DVM, Ph.D.^3,4, Vivek M Rangnekar, Ph.D.^1,2^* and Subbarao Bondada, Ph.D.¹^*

¹Microbiology, Immunology, and Molecular Genetics and Markey Cancer Center, University of Kentucky, Lexington, KY
²Department of Radiation Medicine, University of Kentucky, Lexington, KY
³Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
⁴Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH

See more of: CLL: Biology and Pathophysiology, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

641.P1.80 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I